Literature DB >> 26684922

Resting Hyperperfusion of the Hippocampus, Midbrain, and Basal Ganglia in People at High Risk for Psychosis.

Paul Allen1, Christopher A Chaddock1, Alice Egerton1, Oliver D Howes1, Ilaria Bonoldi1, Fernando Zelaya1, Sagnik Bhattacharyya1, Robin Murray1, Philip McGuire1.   

Abstract

OBJECTIVE: Animal models suggest that the development of psychosis involves hyperactivity in the hippocampus that drives increased activity in the midbrain and basal ganglia. The authors examined this hypothesis by measuring resting perfusion in the hippocampus, basal ganglia, and midbrain in people at high risk of psychosis.
METHOD: Pseudo-continuous arterial spin labeling imaging was used to measure resting regional cerebral blood flow (rCBF) in 52 individuals at ultra-high risk for psychosis and in 27 healthy volunteers. The severity of psychotic symptoms was assessed using the Comprehensive Assessment of At-Risk Mental States. The ultra-high-risk subjects were reassessed after a mean of 17 months, using the same measures as at baseline.
RESULTS: At baseline, relative to healthy volunteers, ultra-high-risk subjects showed elevated rCBF in the hippocampus, basal ganglia, and midbrain. In the ultra-high-risk sample overall, at follow-up, symptomatic improvement and reduced rCBF in the hippocampus and ventral striatum were observed. Subjects whose symptoms had resolved such that they no longer met ultra-high-risk criteria showed a longitudinal reduction in left hippocampal rCBF that was not evident in subjects who remained in a high-risk state or had become psychotic.
CONCLUSIONS: A high risk for psychosis was associated with increased resting activity in the hippocampus, midbrain, and basal ganglia. Subsequent resolution of the high-risk state was linked to a normalization of activity in these regions. These findings are consistent with animal models that propose that psychotic symptoms may be generated when hippocampal hyperactivity drives hyperactivity in regions involved in subcortical dopamine signaling.

Entities:  

Mesh:

Year:  2015        PMID: 26684922     DOI: 10.1176/appi.ajp.2015.15040485

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  50 in total

1.  Cerebral blood flow in striatal regions is associated with apathy in patients with schizophrenia.

Authors:  Karoline Schneider; Lars Michels; Matthias N Hartmann-Riemer; Achim Burrer; Philippe N Tobler; Philipp Stämpfli; Matthias Kirschner; Erich Seifritz; Stefan Kaiser
Journal:  J Psychiatry Neurosci       Date:  2019-03-01       Impact factor: 6.186

2.  Heritability of Cerebral Blood Flow and the Correlation to Schizophrenia Spectrum Disorders: A Pseudo-continuous Arterial Spin Labeling Twin Study.

Authors:  Christian S Legind; Brian V Broberg; Rachel Brouwer; René C W Mandl; Bjørn H Ebdrup; Simon J Anhøj; Maria H Jensen; Rikke Hilker; Birgitte Fagerlund; Hilleke E Hulshoff Pol; Birte Y Glenthøj; Egill Rostrup
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

3.  Correlation Between Levels of Delusional Beliefs and Perfusion of the Hippocampus and an Associated Network in a Non-Help-Seeking Population.

Authors:  Rick P F Wolthusen; Garth Coombs; Emily A Boeke; Stefan Ehrlich; Stephanie N DeCross; Shahin Nasr; Daphne J Holt
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-07-13

4.  Association of sFlt-1 and worsening psychopathology in relatives at high risk for psychosis: A longitudinal study.

Authors:  Paulo L Lizano; Jeffrey K Yao; Neeraj Tandon; Suraj Sarvode Mothi; Debra M Montrose; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2016-11-15       Impact factor: 4.939

5.  Increased Striatal and Reduced Prefrontal Cerebral Blood Flow in Clinical High Risk for Psychosis.

Authors:  Jochen Kindler; Frauke Schultze-Lutter; Martinus Hauf; Thomas Dierks; Andrea Federspiel; Sebastian Walther; Benno G Schimmelmann; Daniela Hubl
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

6.  Anterior Hippocampal-Cortical Functional Connectivity Distinguishes Antipsychotic Naïve First-Episode Psychosis Patients From Controls and May Predict Response to Second-Generation Antipsychotic Treatment.

Authors:  Esther M Blessing; Vishnu P Murty; Botao Zeng; Jijun Wang; Lila Davachi; Donald C Goff
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

Review 7.  [Twelve years of research domain criteria in psychiatric research and practice: claim and reality].

Authors:  Dusan Hirjak; Emanuel Schwarz; Andreas Meyer-Lindenberg
Journal:  Nervenarzt       Date:  2021-08-03       Impact factor: 1.214

8.  Glutamate Dehydrogenase-Deficient Mice Display Schizophrenia-Like Behavioral Abnormalities and CA1-Specific Hippocampal Dysfunction.

Authors:  Sharon S Lander; Usman Khan; Nicole Lewandowski; Darpan Chakraborty; Frank A Provenzano; Susana Mingote; Sergiy Chornyy; Francesca Frigerio; Pierre Maechler; Hanoch Kaphzan; Scott A Small; Stephen Rayport; Inna Gaisler-Salomon
Journal:  Schizophr Bull       Date:  2019-01-01       Impact factor: 9.306

9.  Increased Resting Hippocampal and Basal Ganglia Perfusion in People at Ultra High Risk for Psychosis: Replication in a Second Cohort.

Authors:  Paul Allen; Matilda Azis; Gemma Modinos; Matthijs G Bossong; Ilaria Bonoldi; Carly Samson; Beverly Quinn; Matthew J Kempton; Oliver D Howes; James M Stone; Maria Calem; Jesus Perez; Sagnik Bhattacharayya; Matthew R Broome; Anthony A Grace; Fernando Zelaya; Philip McGuire
Journal:  Schizophr Bull       Date:  2018-10-17       Impact factor: 9.306

10.  Neural Circuitry of Novelty Salience Processing in Psychosis Risk: Association With Clinical Outcome.

Authors:  Gemma Modinos; Paul Allen; Andre Zugman; Danai Dima; Matilda Azis; Carly Samson; Ilaria Bonoldi; Beverly Quinn; George W G Gifford; Sophie E Smart; Mathilde Antoniades; Matthijs G Bossong; Matthew R Broome; Jesus Perez; Oliver D Howes; James M Stone; Anthony A Grace; Philip McGuire
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.